<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04702503</url>
  </required_header>
  <id_info>
    <org_study_id>MB-201</org_study_id>
    <nct_id>NCT04702503</nct_id>
  </id_info>
  <brief_title>Study of WP1220 for the Treatment of Adult Subjects With Cutaneous T-Cell Lymphoma (CTCL)</brief_title>
  <official_title>A Phase 1b Study Evaluating the Safety and Efficacy of Topical Administration of WP1220, an Inhibitor of STAT3 Activation, in Adults With Stage I, II, or III Mycosis Fungoides (Cutaneous T-Cell Lymphoma, CTCL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Moleculin Biotech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Moleculin Biotech, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single center, pilot study to evaluate the safety and efficacy topical administration of&#xD;
      WP1220 in subjects with Stage I, II or III Mycosis Fungoides (CTCL)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 8, 2019</start_date>
  <completion_date type="Actual">November 15, 2020</completion_date>
  <primary_completion_date type="Actual">November 15, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of the safety profile of WP1220 applied topically (adverse events)</measure>
    <time_frame>12 weeks (3 28-day cycles)</time_frame>
    <description>Safety will be evaluated by reported adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of WP1220 applied topically to index lesions via standard measurement scale</measure>
    <time_frame>12 weeks</time_frame>
    <description>Efficacy to be demonstrated through ≥50% improvement in standard assessments of lesions in comparison to baseline.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Cutaneous T-Cell Lymphoma/Mycosis Fungoides</condition>
  <arm_group>
    <arm_group_label>10% WP1220 ointment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10% WP1220 ointment topically applied 2x day for 84 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>WP1220</intervention_name>
    <description>Topical administration 2x daily for 84 consecutive days</description>
    <arm_group_label>10% WP1220 ointment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years at the time of signing informed consent.&#xD;
&#xD;
          2. Clinical diagnosis of MF.&#xD;
&#xD;
          3. Stage IA, IB, IIA, IIB, or II MF: T1-T4 with measurable lesions&#xD;
&#xD;
          4. Previously treatment with at least one standard therapy used to treat Stage IA, IB,&#xD;
             IIA, IIB, or III MF.&#xD;
&#xD;
          5. Measurable skin disease must have at least 2 eligible baseline index lesions with&#xD;
             maximum total area ≤ 40 cm2. Eligible lesions must be below the head (face and scalp&#xD;
             are excluded) and must not involve the genitalia or anus.&#xD;
&#xD;
          6. ECOG performance status of 0-2&#xD;
&#xD;
          7. Subject must read and sign informed consent form and be willing to comply with the&#xD;
             instructions, restrictions, nature and procedures of the study.&#xD;
&#xD;
          8. Willing to avoid tanning devices or exposure of the treated skin to the sun.&#xD;
&#xD;
          9. Willing to not use cosmetics, including lotions, creams, and moisturizers on the&#xD;
             treated lesions.&#xD;
&#xD;
         10. Willing to use topical steroid on a maximum of 25% of BSA occupied by MF on areas not&#xD;
             involved in the clinical trial.&#xD;
&#xD;
         11. Must have recovered from the effects of surgery requiring general anesthesia and&#xD;
             intubation for a minimum of 3 months, and from minor surgery requiring only local&#xD;
             anesthetic for a minimum of 2 weeks.&#xD;
&#xD;
         12. Concomitant disease must be stable and subjects must be on the same dose and schedule&#xD;
             of any medications for at least 1 month before screening.&#xD;
&#xD;
         13. Subjects of both genders who are of childbearing potential including perimenopausal&#xD;
             women who are fewer than 2 years from their last menses, must use one of the following&#xD;
             effective means of contraceptionL&#xD;
&#xD;
               -  Birth control pills in conjunction with spermicide gel&#xD;
&#xD;
               -  Surgical sterilization&#xD;
&#xD;
               -  Intra uterine device&#xD;
&#xD;
               -  Condom and spermicide gel together&#xD;
&#xD;
               -  Sexual abstinence during study period&#xD;
&#xD;
        The requirements above do not apply to:&#xD;
&#xD;
          -  Postmenopausal women with spontaneous amenorrhea for at least 2 years, or&#xD;
&#xD;
          -  Subjects with bilateral oophoerctomy with or without a hysterectomy and an absence of&#xD;
             bleeding for at least 6 months, or&#xD;
&#xD;
          -  Subjects with total hysterectomy and an absence of bleeding for at least 3 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. MF with no prior therapy.&#xD;
&#xD;
          2. Subjects with a diagnosis of stage IV MF at Screening or subsequently observed at&#xD;
             Baseline.&#xD;
&#xD;
          3. Subjects with unusual phenotypes, e.g. lymphomatoid papulosis MF-like type.&#xD;
&#xD;
          4. Subjects who require immediate treatment for progressive MF.&#xD;
&#xD;
          5. Subjects treated with at least one of the following methods within 8 weeks prior to&#xD;
&#xD;
             Baseline:&#xD;
&#xD;
               -  Total body electron beam radiation&#xD;
&#xD;
               -  Investigational drugs or treatments&#xD;
&#xD;
          6. Subjects treated with at least one of the following methods within 4 weeks prior to&#xD;
&#xD;
             Baseline:&#xD;
&#xD;
               -  Local radiation therapy&#xD;
&#xD;
               -  UVB therapy&#xD;
&#xD;
               -  PUVA&#xD;
&#xD;
               -  Topical chemotherapy&#xD;
&#xD;
               -  Topical corticosteroids or retinoids&#xD;
&#xD;
               -  Systemic chemotherapeutic agents (excluding low doses of MTX max. 25 mg/wk)&#xD;
&#xD;
          7. Index lesion treatment with at least one of the following methods within 2 weeks prior&#xD;
             to Baseline:&#xD;
&#xD;
               -  Any surgical procedures other than biopsies related to CTCL diagnosis or follow-&#xD;
                  up&#xD;
&#xD;
               -  Any topical treatment other than bland moisturizers (creams, lotions, emollients,&#xD;
                  etc)&#xD;
&#xD;
          8. Skin infections on screening or baseline involving index lesions planned to be treated&#xD;
             in the clinical trial.&#xD;
&#xD;
          9. The presence of any clinically significant laboratory abnormalities at screening&#xD;
             including, but not limited to abnormalities of the white blood count, hemoglobin,&#xD;
             platelets, serum chemistry (glucose, uric acid, calcium, phosphorus, sodium,&#xD;
             potassium, chloride, alkaline phosphatase, albumin and total bilirubin), thyroid&#xD;
             stimulating hormone, fT3 and fT4 as determined by the Investigator in conjunction with&#xD;
             the Medical Monitor.&#xD;
&#xD;
         10. Any significant uncontrolled medical disease as evaluated by the Investigator and/or&#xD;
             Medical Monitor, chronic or active within the past 6 months, including but not limited&#xD;
             to, cardiac disease, seizure disorder, liver disease, renal disease, chronic&#xD;
             infection, uncontrolled diabetes, lung disease.&#xD;
&#xD;
         11. Any prior history or active malignancy other than MF.&#xD;
&#xD;
         12. Subjects in deep depression.&#xD;
&#xD;
         13. Subjects who are not mentally capable of understanding the protocol and all&#xD;
             procedures.&#xD;
&#xD;
         14. Subjects who do not agree to have the necessary blood draws and procedures for&#xD;
             laboratory tests and evaluations according to protocol.&#xD;
&#xD;
         15. Known allergy to any active or inactive ointment ingredient.&#xD;
&#xD;
         16. Pregnant and nursing women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandra Silberman, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Moleculin Biotech, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of Gdansk</name>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>March 19, 2019</study_first_submitted>
  <study_first_submitted_qc>January 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 11, 2021</study_first_posted>
  <last_update_submitted>January 8, 2021</last_update_submitted>
  <last_update_submitted_qc>January 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Mycosis Fungoides</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Cutaneous</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

